- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05245812
Seguridad y viabilidad de la mastectomía robótica con preservación del pezón SP
Seguridad y viabilidad de la mastectomía robótica con preservación del pezón por un solo puerto (SP): ensayo piloto de una sola institución y un solo brazo
This is a single arm, single-center, prospective clinical trial designed to track the peri, post-operative and oncologic outcomes when utilizing the da-Vinci single port (SP) robotic platform to perform robotic nipple sparing mastectomy (rNSM) and immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (ADM - Alloderm), for patients with breast cancer as well as those with a high risk for breast cancer.
Safety and feasibility measures will be measured as primary outcome measures. Oncological and patient satisfaction outcome measures will be measured. Our hypothesis is that SPr-NSM is equal to open NSM in terms of safety, feasibility and oncological outcomes with improved patient satisfaction as measured by nipple sensation and patient reported outcomes.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
rNSM using the multi-port robotic platform followed by standard of care open breast reconstruction has been done successfully at multiple institutions worldwide with comparable, if not superior outcomes to an open surgical approach. This study explores this procedure with the Da Vinci SP robot with pre-pectoral reconstruction with acellular dermal matrix. The patients will be evaluated per standard of care post-operative visits at 2 weeks, 1 month, and every 6 months for five years post operatively for subjective patient satisfaction and objectively for post-operative nipple sensation. The patients will be monitored longitudinally for oncologic outcomes including the presence of a new breast cancer and/or breast cancer recurrence. Patients will be monitored for any complications related to rNSM and the use of ADM in expander and implant-based breast reconstruction.
Investigational Device:
The da Vinci SP Surgical System, Model SP1098 is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery. The Model SP1098 Surgical System consists of a Surgeon Console, a Patient Cart, and a Vision Cart, and is used with a Camera Instrument, EndoWrist SP Instruments, and Accessories.
Indications for Use:
The da Vinci SP Surgical System, Model SP1098 is cleared for use in urologic surgical procedures that are appropriate for a single-port approach and transoral otolaryngology procedures restricted to T1 and T2 tumors. This investigational study will evaluate device usage in nipple sparing mastectomy (NSM) procedures.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Deborah Farr, MD, FACS
- Número de teléfono: 214-648-4133
- Correo electrónico: Deborah.Farr@UTSouthwestern.edu
Ubicaciones de estudio
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Reclutamiento
- UT Southwestern
-
Contacto:
- Deborah E Farr, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Candidates for open nipple sparing mastectomy, per standard of care with regards to anatomic factors and tumor location including: nipple sparing resection and resection OR prophylactic mastectomy for risk reduction OR treatment of ductal carcinoma in-situ or clinically node negative cT1-T3 breast cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria:
- Inability to provide informed consent
- Pregnant or nursing women
- Patients with:
- Inflammatory breast cancer
- Skin involvement with tumor
- Pre-operative diagnosis of Nipple Areolar Complex (NAC) tumor involvement
- Grade 3 or higher nipple ptosis
- Contraindicated for general anesthesia or surgery
- Heavy current smoking history (defined as > 20 cigarettes per day)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Treatment arm (SPrNSM)
Patients will undergo Single Port robotic Nipple Sparing Mastectomy (SPrNSM) with immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (Alloderm) |
This is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants who complete single port nipple sparing mastectomy (SPrNSM)
Periodo de tiempo: Date of surgery (Day 1)
|
The number of participants who complete single port nipple sparing mastectomy (SPrNSM) will be measured. |
Date of surgery (Day 1)
|
|
Incidence of perioperative complications
Periodo de tiempo: 30 days following surgery
|
Perioperative complications will be described using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTACAE) v. 4.03 criteria. Complications will refer to any medical occurrence directly attributed to the surgical procedure during and within the first 30 days following use of the SP robotic platform and ADM. Grade 3, 4, or 5 complication or adverse event will constitute an event. Perioperative complication rates will be compared to historical complication rates. |
30 days following surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants with positive margins
Periodo de tiempo: 2 weeks following date of surgery
|
The pathologist will assess margin status in patients undergoing SPrNSM |
2 weeks following date of surgery
|
|
Number of participants with new breast cancers
Periodo de tiempo: following date of surgery up to 5 years
|
The PI will assess new breast cancers. |
following date of surgery up to 5 years
|
|
Number of participants with recurrent breast cancers
Periodo de tiempo: following date of surgery up to 5 years
|
The PI will assess recurrent breast cancers. |
following date of surgery up to 5 years
|
|
Patient satisfaction as measured by BREAST-Q reconstruction tool
Periodo de tiempo: Baseline, postoperatively at 2 weeks, every 6 months for 5 years
|
Patient satisfaction is measured by BREAST-Q reconstruction tool at baseline, postoperatively at 2 weeks, and every 6 months for 5 years. BREAST-Q reconstruction module and Breast implant illness survey for patients. Questions about self-confidence, comfort, acceptance of new appearance, feeling of implants, breast pain. The score represents questionnaires about different domains and each question has four possible dimensions. The values of these dimensions varies from 1 (minimum score- worst outcome) to 4 or 5 (maximum score- best outcome) (Likert Scale) depending on part of the questionnaire . |
Baseline, postoperatively at 2 weeks, every 6 months for 5 years
|
|
Patient satisfaction as measured by BREAST-Q sensation tool
Periodo de tiempo: Baseline, postoperatively at 2 weeks, every 6 months for 5 years
|
Patient satisfaction is measured by BREAST-Q sensation tool at baseline, postoperatively at 2 weeks, and every 6 months for 5 years and it is another tool to help quantify breast sensation both pre-operatively and post-operatively. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains: i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome and 3 well-being sub-domains: i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being. The values range from 1 (minimum score- worst outcome) to 4 or 5 (maximum score- best outcome) (Likert Scale) depending on part of the questionnaire. |
Baseline, postoperatively at 2 weeks, every 6 months for 5 years
|
|
Degree to which the patients maintain nipple sensation as measured by Semmes Weinstein monofilament tool at baseline
Periodo de tiempo: Baseline, postoperatively at 2 weeks, every 6 months for 5 years
|
Degree to which the patients maintain nipple sensation will be measured by Semmes Weinstein monofilament tool at baseline, postoperatively at 2 weeks, and every 6 months for 5 years. Monofilament diameter and force will be measured at 9 different locations of the breast to determine the degree of sensation. |
Baseline, postoperatively at 2 weeks, every 6 months for 5 years
|
|
Incidence of short term complications
Periodo de tiempo: Post-operatively at 30 days
|
Reconstruction outcomes is measured by short term complications (wounds, infections, seromas, and device exchange or loss) that occur post-operatively after surgery Short term complications will be described using the NCI CTACAE v. 4.03 criteria. |
Post-operatively at 30 days
|
|
Incidence of long term complications
Periodo de tiempo: Following surgery up to 5 years
|
Long term complications will be described using the NCI CTACAE v. 4.03 criteria and will refer to any medical occurrence directly attributed to the surgical procedure up to 5 years following use of the SP robotic platform and ADM. Grade 3, 4, or 5 complication or adverse event will constitute an event. |
Following surgery up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Deborah Farr, MD, FACS, University of Texas Southwestern Medical Center
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- STU-2022-0091
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .